Literature DB >> 21783380

Estimating viral titres in solutions with low viral loads.

C Brownie1, J Statt, P Bauman, G Buczynski, K Skjolaas, D Lee, J Hotta, N J Roth.   

Abstract

An important consideration in the manufacture of products derived from animal or human sources is the virus reduction capacity of the manufacturing process as estimated using validated bench-scale models of relevant manufacturing steps. In these studies, manufacturing process intermediates are spiked with virus and processed using the bench-scale model and the resulting viral titres of input and output samples are typically determined using cell-based infectivity assays. In these assays, the Spearman-Kärber (SK) method is commonly used to estimate titres when there is one or more positive observation (i.e., the presence of any viral cytopathic effect). The SK method is most accurate when the proportion of positive observations ranges from <0.1 to >0.9 across dilutions but can be biased otherwise. Maximum likelihood (ML) based on a single-hit Poisson model is an alternative widely used estimation method. We compared SK with ML and found the methods to have similar properties except for situations in which the concentration of virus is low but measurable. In this case, the SK method produces upwardly biased estimates of titres. Based on our results, we recommend the use of either ML or SK at most virus concentrations; however, at low virus concentrations ML is preferred.
Copyright © 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21783380     DOI: 10.1016/j.biologicals.2011.06.007

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  6 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.

Authors:  Petra van den Doel; Asisa Volz; Jouke M Roose; Varsha D Sewbalaksing; Gorben P Pijlman; Ingeborg van Middelkoop; Vincent Duiverman; Eva van de Wetering; Gerd Sutter; Albert D M E Osterhaus; Byron E E Martina
Journal:  PLoS Negl Trop Dis       Date:  2014-09-04

3.  Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.

Authors:  Kai Uwe Radomski; Georg Lattner; Torben Schmidt; Jürgen Römisch
Journal:  BioDrugs       Date:  2017-04       Impact factor: 5.807

4.  Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector for poultry vaccination.

Authors:  Yashar Sadigh; Claire Powers; Simon Spiro; Miriam Pedrera; Andrew Broadbent; Venugopal Nair
Journal:  NPJ Vaccines       Date:  2018-05-28       Impact factor: 7.344

5.  Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus.

Authors:  Stefan J Halbherr; Terza Brostoff; Merve Tippenhauer; Samira Locher; Marianne Berger Rentsch; Gert Zimmer
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

6.  Heat-Treated Virus Inactivation Rate Depends Strongly on Treatment Procedure: Illustration with SARS-CoV-2.

Authors:  Amandine Gamble; Robert J Fischer; Dylan H Morris; Claude Kwe Yinda; Vincent J Munster; James O Lloyd-Smith
Journal:  Appl Environ Microbiol       Date:  2021-07-21       Impact factor: 4.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.